Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03831880 · ClinicalTrials.gov registry record · Phase 3
Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
NCT03831880 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 87 participants.
The verdict
NCT03831880, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
Study Summary
This is an open label randomized 24 week crossover trial assessing the treatment burden of a weekly growth hormone injection regimen (somatrogon) compared to a daily growth hormone injection regimen (Genotropin). Approximately 90 children with growth hormone deficiency who have been stable on treatment with daily Genotropin will be enrolled.
Interventions
- DRUG Genotropin
- DRUG somatrogon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2020-08-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03831880
The ClinicalTrials.gov registry entry for NCT03831880 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Genotropin is the first listed.
NCT03831880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03831880 about?
NCT03831880 is a clinical study titled "Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD". This is an open label randomized 24 week crossover trial assessing the treatment burden of a weekly growth hormone injection regimen (somatrogon) compared to a daily growth hormone injection regimen (Genotropin). Approximately 90 children with growth hormone deficiency who have been stable on treatm...
What is the current status of trial NCT03831880?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2019-02-07. Estimated completion is 2020-08-28.
What interventions are being tested in trial NCT03831880?
The interventions under investigation include: Genotropin (DRUG), somatrogon (DRUG).
Who is sponsoring clinical trial NCT03831880?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.